Albumin–bilirubin (ALBI) was first attempted to assess the liver function reserve of patients diagnosed with hepatocellular carcinoma (HCC) the same as the Child–Pugh grade in 2015, but ALBI had better predictive ability than the Child–Pugh grade for postoperative liver failure and long-term survival of patients undergoing liver resection (7, 8). This evidence concerns the gene ALB and hepatocellular carcinoma.